We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

Aspen Pharmacare, SA’s biggest pharmaceutical manufacturer, is in discussions to expand its vaccine production capacity beyond Covid-19 to jabs for other diseases, CEO Stephen Saad said on Thursday.

Aspen has the capacity to produce up to 1.35-billion vaccine doses at its sterile manufacturing facility in Gqeberha, and is currently using less than a quarter of that capacity to help make Johnson & Johnson’s (J&J)’s Covid-19 shot. It aims to ramp up Covid-19 vaccine production from 300-million to 450-million doses a year by February, and to 700-million doses a year by January 2023, but would still have scope to make other kinds of shots, said Saad...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now